Please login to the form below

Not currently logged in
Email:
Password:

Circassia

This page shows the latest Circassia news and features for those working in and with pharma, biotech and healthcare.

Circassia exits allergy R&D after placebo effect strikes again

Circassia exits allergy R&D after placebo effect strikes again

Circassia exits allergy R&D after placebo effect strikes again. Abandons phase IIb trial of house dust mite allergy candidate. ... That deal was valued at up to $230m, with Circassia giving AZ $50m in shares in return for the rights to the two drugs.

Latest news

  • Circassia slumps as cat allergy vaccine fails late-stage trial Circassia slumps as cat allergy vaccine fails late-stage trial

    Circassia slumps as cat allergy vaccine fails late-stage trial. Has suspended several trials after an “ unprecedented” placebo effect derailed leading drug candidate. ... UK biotech Circassia Pharma has suffered a major blow as its lead cat allergy

  • Allergy specialist Circassia buys asthma firms Allergy specialist Circassia buys asthma firms

    Allergy specialist Circassia buys asthma firms. British-based company acquires Sweden’ s Aerocrine and privately held Prosonix. ... Circassia will pay £139m ($219m) for Aerocrine and up to £100m for Prosonix.

  • The M&A trend in pharma The M&A trend in pharma

    Pet allergy (and biotech) company Circassia's £200m IPO has so far represented the largest of these deals in the life sciences sector this year.

  • Lilly invests in UK life sciences via biotech fund Lilly invests in UK life sciences via biotech fund

    This year has already seen allergy specialist Circassia raise £200m in an initial public offering (IPO) after years in which a small biotech companies had to partner with a larger company

  • TxCell plans listing as EU biotech wakes up to IPOs

    TxCell plans listing as EU biotech wakes up to IPOs. Move follows UK allergy therapy developer Circassia's listing. ... TxCell's move comes shortly after UK allergy therapy developer Circassia raised £200m ($333m) via an IPO on the London Stock Exchange

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    One of Imperial College’s research ventures has culminated in the development of Circassia Pharmaceuticals, a spin-out biotech whose co-founders were at the time testing a prototype vaccine technology ... This year, Circassia established a commercial

  • Deal Watch March 2017 Deal Watch March 2017

    If Circassia sublicenses the rights to Tudorza in the US, it will pay a further $80m. ... 250. AstraZeneca. Circassia Pharmaceuticals. Strategic collaboration. Tudorza (marketed) and Duaklir (phase III) in COPD.

  • Pharma deals in May 2015 Pharma deals in May 2015

    155. Prosonix/Circassia. Corporate acquisition. Portfolio of generic respiratory products includingfluticasone. 152.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics